The University of Southampton
University of Southampton Institutional Repository

Sublingual tablet immunotherapy improves quality of life in adults with allergic rhinoconjunctivitis

Sublingual tablet immunotherapy improves quality of life in adults with allergic rhinoconjunctivitis
Sublingual tablet immunotherapy improves quality of life in adults with allergic rhinoconjunctivitis

Background: Allergic rhinitis with or without conjunctivitis can negatively impact many aspects of quality of life (QoL). The efficacy and safety of standardized quality (SQ) sublingual immunotherapy (SLIT) tablets have been confirmed across large clinical trials in adults with grass, tree, ragweed, and house dust mite (HDM) allergic rhinitis with or without conjunctivitis. Objective: This pooled analysis investigates whether the reduction in symptom burden found across the clinical trials is supported by improvements in QoL. Methods: A total of 11 phase II/III randomized placebo-controlled trials across the SQ grass, tree, ragweed, and HDM SLIT tablets (grass: N = 3179; ragweed: N = 767; tree: N = 634; HDM: N = 2221) were included. QoL was assessed using the standardized Rhinitis Quality of Life Questionnaire (RQLQ), with the exception of 3 grass trials, which used the nonstandardized version. The overall RQLQ scores were expressed as a mean of 7 domains. In the pooled analysis, treatment was used as fixed effect; and the trial, and the interaction between region/country and trial as random effects. Results: The pooled analysis showed consistent and statistically significant improvements in overall RQLQ scores across all 4 SQ SLIT tablets versus placebo (pooled estimate [95% CI], P value—grass: −0.20 [−0.28 to −0.12], P < .001; tree: −0.42 [−0.58 to −0.26], P < .001; ragweed: −0.36 [−0.55 to −0.17], P < .001; HDM: −0.28 [−0.39 to −0.17], P < .001). Furthermore, significant improvements versus placebo for all 4 SQ SLIT tablets were seen across the 7 individual domains. Conclusions: The proven efficacy of SQ SLIT tablets to reduce symptoms across 4 of the most common respiratory allergens is supported by concurrent significant improvements in RQLQ scores overall and for all 7 domains.

Allergic rhinoconjunctivitis, Grass pollen allergy, HDM allergy, Pooled analysis, Quality of life, RQLQ, RQLQ domains, Ragweed allergen, Sublingual immunotherapy, Tree pollen allergy
2213-2198
1520-1529.e5
Blaiss, Michael S
5bfffae8-a07d-4a12-bf0d-ba8553b7b837
Durham, Stephen R.
2c4a2deb-84be-4796-9566-fdcddfe29d8b
Bernstein, David
09f7ab15-a526-4e48-9d8f-2653c3baf86b
Stranzl, Thomas
f146fd5f-ab9a-43af-bbfc-ce65c1e43c58
Lindholm, Morten
c0ec96ba-52ce-4137-910a-a00302b5e94f
Nolte, Hendrik
1f5625c7-8379-4398-bf26-51eb194edc5c
Andersen, Kristian Funding
e1c18fbf-3ee6-4d4d-b9e9-2519f4e3bbcf
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
Blaiss, Michael S
5bfffae8-a07d-4a12-bf0d-ba8553b7b837
Durham, Stephen R.
2c4a2deb-84be-4796-9566-fdcddfe29d8b
Bernstein, David
09f7ab15-a526-4e48-9d8f-2653c3baf86b
Stranzl, Thomas
f146fd5f-ab9a-43af-bbfc-ce65c1e43c58
Lindholm, Morten
c0ec96ba-52ce-4137-910a-a00302b5e94f
Nolte, Hendrik
1f5625c7-8379-4398-bf26-51eb194edc5c
Andersen, Kristian Funding
e1c18fbf-3ee6-4d4d-b9e9-2519f4e3bbcf
Roberts, Graham
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3

Blaiss, Michael S, Durham, Stephen R., Bernstein, David, Stranzl, Thomas, Lindholm, Morten, Nolte, Hendrik, Andersen, Kristian Funding and Roberts, Graham (2024) Sublingual tablet immunotherapy improves quality of life in adults with allergic rhinoconjunctivitis. Journal of Allergy and Clinical Immunology: In Practice, 12 (6), 1520-1529.e5. (doi:10.1016/j.jaip.2024.01.038).

Record type: Article

Abstract

Background: Allergic rhinitis with or without conjunctivitis can negatively impact many aspects of quality of life (QoL). The efficacy and safety of standardized quality (SQ) sublingual immunotherapy (SLIT) tablets have been confirmed across large clinical trials in adults with grass, tree, ragweed, and house dust mite (HDM) allergic rhinitis with or without conjunctivitis. Objective: This pooled analysis investigates whether the reduction in symptom burden found across the clinical trials is supported by improvements in QoL. Methods: A total of 11 phase II/III randomized placebo-controlled trials across the SQ grass, tree, ragweed, and HDM SLIT tablets (grass: N = 3179; ragweed: N = 767; tree: N = 634; HDM: N = 2221) were included. QoL was assessed using the standardized Rhinitis Quality of Life Questionnaire (RQLQ), with the exception of 3 grass trials, which used the nonstandardized version. The overall RQLQ scores were expressed as a mean of 7 domains. In the pooled analysis, treatment was used as fixed effect; and the trial, and the interaction between region/country and trial as random effects. Results: The pooled analysis showed consistent and statistically significant improvements in overall RQLQ scores across all 4 SQ SLIT tablets versus placebo (pooled estimate [95% CI], P value—grass: −0.20 [−0.28 to −0.12], P < .001; tree: −0.42 [−0.58 to −0.26], P < .001; ragweed: −0.36 [−0.55 to −0.17], P < .001; HDM: −0.28 [−0.39 to −0.17], P < .001). Furthermore, significant improvements versus placebo for all 4 SQ SLIT tablets were seen across the 7 individual domains. Conclusions: The proven efficacy of SQ SLIT tablets to reduce symptoms across 4 of the most common respiratory allergens is supported by concurrent significant improvements in RQLQ scores overall and for all 7 domains.

Text
1-s2.0-S2213219824001405-main - Proof
Download (3MB)

More information

Accepted/In Press date: 25 January 2024
e-pub ahead of print date: 1 February 2024
Published date: June 2024
Additional Information: Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.
Keywords: Allergic rhinoconjunctivitis, Grass pollen allergy, HDM allergy, Pooled analysis, Quality of life, RQLQ, RQLQ domains, Ragweed allergen, Sublingual immunotherapy, Tree pollen allergy

Identifiers

Local EPrints ID: 487221
URI: http://eprints.soton.ac.uk/id/eprint/487221
ISSN: 2213-2198
PURE UUID: 73ea6f8f-3057-40de-bd0f-335bfb1ed882
ORCID for Graham Roberts: ORCID iD orcid.org/0000-0003-2252-1248

Catalogue record

Date deposited: 16 Feb 2024 11:24
Last modified: 14 Aug 2024 01:40

Export record

Altmetrics

Contributors

Author: Michael S Blaiss
Author: Stephen R. Durham
Author: David Bernstein
Author: Thomas Stranzl
Author: Morten Lindholm
Author: Hendrik Nolte
Author: Kristian Funding Andersen
Author: Graham Roberts ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×